Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Published:2017-11 Issue:11 Volume:18 Page:1512-1522
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Doi Toshihiko,Shitara Kohei,Naito Yoichi,Shimomura Akihiko,Fujiwara Yasuhiro,Yonemori Kan,Shimizu Chikako,Shimoi Tatsunori,Kuboki Yasutoshi,Matsubara Nobuaki,Kitano Atsuko,Jikoh Takahiro,Lee Caleb,Fujisaki Yoshihiko,Ogitani Yusuke,Yver Antoine,Tamura Kenji

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann Oncol,2008

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

4. HER2 aberrations in cancer: implications for therapy;Yan;Cancer Treat Rev,2014

5. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

2. Novel antibody-drug conjugates based on DXd-ADC technology;Bioorganic Chemistry;2024-10

3. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

4. Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?;The Lancet Oncology;2024-09

5. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial;The Lancet Oncology;2024-09